Pennant Investors LP Acquires Shares of 48,500 uniQure (NASDAQ:QURE)

Pennant Investors LP bought a new position in shares of uniQure (NASDAQ:QURE) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 48,500 shares of the biotechnology company’s stock, valued at approximately $328,000. Pennant Investors LP owned approximately 0.10% of uniQure at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quantbot Technologies LP boosted its holdings in uniQure by 1,194.7% in the third quarter. Quantbot Technologies LP now owns 24,600 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,700 shares during the last quarter. Swiss National Bank boosted its stake in shares of uniQure by 8.0% during the 3rd quarter. Swiss National Bank now owns 99,400 shares of the biotechnology company’s stock valued at $667,000 after buying an additional 7,400 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of uniQure during the third quarter worth approximately $31,000. Citigroup Inc. increased its stake in shares of uniQure by 667.9% in the third quarter. Citigroup Inc. now owns 766,521 shares of the biotechnology company’s stock worth $5,143,000 after buying an additional 666,696 shares during the last quarter. Finally, E Fund Management Co. Ltd. increased its stake in shares of uniQure by 88.4% in the third quarter. E Fund Management Co. Ltd. now owns 20,075 shares of the biotechnology company’s stock worth $135,000 after buying an additional 9,422 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Stock Performance

NASDAQ:QURE traded down $0.23 during midday trading on Tuesday, reaching $5.15. 346,138 shares of the company traded hands, compared to its average volume of 858,699. The firm has a market capitalization of $250.03 million, a price-to-earnings ratio of -0.84 and a beta of 1.08. The company has a fifty day moving average price of $4.90 and a 200 day moving average price of $5.68. The company has a debt-to-equity ratio of 0.70, a current ratio of 9.39 and a quick ratio of 9.27. uniQure has a twelve month low of $4.25 and a twelve month high of $20.41.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.31) by ($0.05). uniQure had a negative net margin of 1,562.22% and a negative return on equity of 121.60%. The firm had revenue of $8.49 million during the quarter, compared to the consensus estimate of $2.58 million. On average, analysts expect that uniQure will post -4.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of uniQure in a report on Wednesday, May 8th. Mizuho lowered their price objective on uniQure from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, May 8th. StockNews.com raised uniQure to a “sell” rating in a report on Friday, March 1st. Finally, The Goldman Sachs Group downgraded uniQure from a “buy” rating to a “neutral” rating and lowered their price target for the company from $63.00 to $8.00 in a report on Thursday, February 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.75.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.